INTRODUCTION
Generally, many diseases are represented with pain. Although pain is a simple condition, but without an appropriate therapy will lead to chronic pain condition. Chronic pain incidence impacts to many several problems in patient life such as economic, social and psychology (Breivik, 2005; Mallen, et al., 2005) . International Association for the study of Pain (IASP) define that pain is an unpleasant sensory and emotional experience, usually associated with actual and potential tissue damage (IASP, 2011) . Chronic pain incidence is the most symptom that was happened in 1 of 6 people on the population (Xie, 2011) . The prevalence of chronic pain in Europe was estimated to 55.2% (Picavet and Schouten, 2003; Harstall and Ospina, 2003) . There were no clearly estimation in Indonesia, but Kartini (2007) showed that 25-50% of geriatry patient have pain. Until now, chronic pain treatment is still a challenge because of its complex mechanism. Morphine as the first treatment have a lot of weakness and the effectiveness of this drug for chronic pain treatment is still debated (Baron et al., 2010; Hahm et al., 2011) . So, we need an alternative new strategy, one of them is GABAergik agonist drugs such as gabapentin and baclofen (Wang et al., 2007) .
INTRODUCTION MATERIALS AND METHODS
treatment in animal have been approved by Animal Care and Use Committee (ACUC) from Faculty of Veterinary Medicine, Airlangga University, Surabaya, East Java, Indonesia.
Molecular Modelling Programs
Computer programs in this research were ChemBioDraw Ultra® 11.0 trial edition (2D structure and determining of physicochemical properties), ChemBio3D Ultra® 11.0 trial edition (3D structure) and Mollegro Virtual Docker 5.0 (Docking).
Experimental Protocol

CFA-induced Chronic Pain Method
Intraplantar injection were performed with a Hamilton syringe coupled to a 26-gauge needle. Fourty microliters of CFA (Sigma-Aldrich) was injected by intraplantar into the plantar surface of the hind paw under aether anesthesia for induction of inflammation in inflammatory (CFA) groups. Control mice (sham group) received fourty microliters normal saline as CFA replacement.
Behavioral Testing Method Animals were placed on a hot plate, which was set to 48±0.5°C, and timing was started immediately.
The time until nociceptive behavior (defined as lifting, shaking, or licking the injured paw) occurred was recorded for each animal and the animal immediately removed from the hot plate. Latency time toward thermal stimulus were measured on day 1, 2, 8, 9, 11 and 15.
Drugs Treatment Gabapentin and baclofen were disolved in physiological saline for intrathecal injection. Intrathecal injections were given in a volume of 5µl. In control mice (sham group) and negative control were given by physiological saline at the same volume. Gabapentin and baclofen were administrated in three different doses, once a day for seven consecutive days, started from day 8 after CFA induction. Gabapentin were given on doses 10,30 and 100 nmol. Baclofen were given on doses 1,10 and 30 nmol.
Statistics Analysis
Data were presented as mean ± SEM. The time latency toward thermal stimulus between inflammatory (CFA) and sham group were analyzed by independent t-test. The time latency toward thermal stimulus between each treatment were analyzed with two-way ANOVA. Differences were considered statistically significant at the p < 0.05 confidence interval.
Molecular docking Analysis
The structures of the compounds under study have been drawn in 2D ChemDraw® and then converted into 3D modules using the default conversion procedure implemented in the CS Chem 3D Ultra®. The generated 3D-structures of the compounds were subsequently subjected to energy minimi- CFA Normal saline 4.5 ± 0.5 4.1 ± 0.4 3.7 ± 0.6 b) Gabapentin 10 nmol 6.2 ± 0.4 8.0 ± 0.2 9.1 ± 0.5 c) Gabapentin 30 nmol 7.6 ± 0.7 8.3 ± 0.6 10.5 ± 0.7 ac) Gabapentin 100 nmol 9.2 ± 0.6 11.0 ± 0.9 12.9 ± 0.4 d) Baclofen 1 nmol 6.5 ± 0.4 7.6 ± 0.5 9.9 ± 0.6 c) Baclofen 10 nmol 7.0 ± 0.4 8.0 ± 0.6 10.4 ± 0.3 a) Baclofen 30 nmol 8.0 ± 0.5 9.2 ± 0.3 11.5 ± 0.6 ad)
Different letters showed there were significant differences of time latency toward thermal stimulus on each treatment (p < 0. 
RESULTS AND DISCUSSION
Inflammation induction by intraplantar injection of CFA caused lowering of latency time toward thermal stimulus than before (baseline). The results were showed at Table 1. After intrathecal injection of gabapentin and baclofen, latency toward thermal stimulus increased to normal (closed to sham group). This results showed that effectiveness gabapentin to increased time latency toward thermal stimulus was reached on dose 30 nmol. In baclofen treatment, 10 nmol doses was given latency toward thermal stimulus as same as sham group. Latency time toward thermal stimulus were significantly different between day 9, 10 and 15. It means that the longer of day treatment, the longer latency time toward thermal stimulus. The results were showed at Table 2 .
There is a relationship between chronic pain and GABA. Pathophysiology of chronic pain showed that chronic pain is caused by imbalance between GABA (as inhibitory neurotransmitter) and Glutamat, especially NMDA subunit NR2B (as excitatory neurotransmitter). GABA agonist administration cause increasing activity of GABA receptor and lead inhibition of NMDA subunit NR2B release. So, it were relevance when gabapentin and baclofen caused increasing of time latency toward thermal stimulus, because both of them worked to stimulate GABA receptor with two different ways. Gabapentin binds to α2δ1 subunit in Ca 2+ canal and inhibits glutamate release (Bee and Dickenson, 2007) . The other side, baclofen is an GABAB agonist receptor that stimulates hiperpolarization by increases K+ influx and decreases Ca 2+ influx and inhibit glutamate release (Bettler, et al., 2004; Benke et al., 2012) .
Based on docking results, gabapentin and baclofen interacted on glutamate site of NR2B subunit. Interaction between gabapentin and baclofen with 
NR2B subunit happened by hydrogen bond on amino acid Gln110 (Figure 1 ). Different from gabapentin, baclofen also bind to Arg115 (Figure 2 ). The binding differences between gabapentin and baclofen, probably have responsibility to different effectiveness between both of them on NR2B subunit. Docking parameter (Table 3) showed that baclofen have rerank score and hydrogen bond value (-84.9504 and -4.47179 ) smaller than gabapentin (-80.5263 and -3.8352 ). Smaller value indicated that binding energy between baclofen and NR2B subunit lower and caused receptor binding more stable than gabapentin. This value, maybe can be used to explain the differences of doses that caused an effectiveness on NR2B subunit inhibition. From the result of latency time toward thermal stimulus showed that effective dose for baclofen was lower (10 nmol) than gabapentin (30 nmol) to interact with NR2B subunit of NMDA receptor.
CONCLUSION
Gabapentin and baclofen were effective for inflammatory-induced chronic pain in mice and showed that both of them caused increasing of latency time toward thermal stimulus. The differences of the effective doses between gabapentin and baclofen were based on differences type of amino acid binding on NR2B subunit.
